Headline News

 

FDA approves Lilly’s Mounjaro (tirzepatide) to lower cardiovascular risk in adults with type 2 diabetes

Posted on September 01, 2026

Eli Lilly to purchase Merida Biosciences in move to strengthen treatments for serious autoimmune and allergic conditions

Posted on September 01, 2026

New Phase 3b findings on Lilly’s Taltz paired with Zepbound show durable, strengthened results at one year in adults living with psoriatic disease and obesity

Posted on September 01, 2026

FDA approves Johnson & Johnson’s IMAAVY as the first treatment ever cleared for warm autoimmune hemolytic anemia, marking a major step forward for patients

Posted on August 25, 2026

Merck and Moderna’s Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA meets endpoints for recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma

Posted on August 25, 2026

Abbott reaches settlement agreements resolving portion of litigation tied to specialty formulas for preterm infants

Posted on August 25, 2026

FDA approves Regeneron’s Pasatru the first treatment shown to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in a placebo-controlled trial for adults with fibrodysplasia ossificans progressiva

Posted on August 25, 2026

BeOne Medicines, BeOne Care Foundation, and The Max Foundation extend collaboration to broaden access to BRUKINSA for chronic lymphocytic leukemia patients in low- and middle-income countries

Posted on August 25, 2026

ORZEYFUL approved in Japan as the first and only medicine to address the underlying cause of narcolepsy type 1

Posted on August 25, 2026

Novartis presents cardiovascular data at ESC Congress 2026, reinforcing its position in heart health and highlighting progress on next-generation therapies

Posted on August 25, 2026

Genentech unveils plans to expand manufacturing operations in the United States

Posted on August 25, 2026

Hibsago receives approval in Japan as the first and only functional cure for chronic hepatitis B

Posted on August 25, 2026

FDA grants priority review to GSK’s Jemperli for dMMR/MSI-H locally advanced rectal cancer

Posted on August 25, 2026

Adneuris Therapeutics grants Maruishi Pharmaceutical exclusive license to develop cebranopadol in Japan and South Korea

Posted on August 18, 2026

Johnson & Johnson introduces MONARCH QUEST 3, the next step forward in robotically assisted bronchoscopy

Posted on August 18, 2026